Compare WBX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | CMPS |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | Spain | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 646.2M |
| IPO Year | N/A | 2020 |
| Metric | WBX | CMPS |
|---|---|---|
| Price | $2.39 | $6.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $9.00 | ★ $16.43 |
| AVG Volume (30 Days) | 33.3K | ★ 1.2M |
| Earning Date | 02-26-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,593,453.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $2.25 |
| 52 Week High | $14.40 | $7.15 |
| Indicator | WBX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 24.77 | 61.86 |
| Support Level | $2.49 | $6.56 |
| Resistance Level | $3.36 | $7.15 |
| Average True Range (ATR) | 0.20 | 0.36 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 6.13 | 71.50 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.